Table 3.
Behaviour of baseline clinical and biochemical values relative to metabolic control in patients who maintained a relatively stable glucose control over the lockdown (Steady) and in those whose glucose control worsened (Worsen)
| Steady (n = 85; 74%) | Worsen (n = 29; 26%) | p value | |
|---|---|---|---|
| Age (years) | 69.1 ± 10.4 | 70.5 ± 10.3 | ns |
| Men (n; %) | 50; 59.5 | 20; 69.0 | ns |
| Disease duration (years) | 8.5 ± 8.1 | 8.0 ± 7.2 | ns |
| BMI (kg/m2) | 28.4 ± 5.3 | 30.0 ± 5.3 | ns |
| Insulin, with or without other agents (n; %) | 14; 16.7 | 8; 27.6 | ns |
| Oral or injective hypoglycaemic agents (n; %) | 66; 78.5 | 21; 72.4 | ns |
| Lifestyle and diet (n; %) | 5; 4.8 | 0; 0.0 | ns |
| Hypolipidemic agents (n; %) | 66; 78.5 | 24; 82.7 | ns |
| Serum creatinine (mg/dl) | 1.0 ± 0.4 | 1.0 ± 0.2 | ns |
| eGFR CKD-EPI (ml/min/1.73 m2) | 79.5 ± 23.0 | 80.8 ± 20.0 | ns |
| Last pre-Ld HbA1c (%; mmol/mol) |
6.6 ± 0.7 48.6 ± 3.5 |
6.7 ± 0.8 49.7 ± 4.0 |
ns |
| Mean pre-Ld HbA1c (%; mmol/mol) |
6.8 ± 0.7 50.8 ± 3.5 |
6.7 ± 0.8 49.7 ± 4.0 |
ns |
| Last pre-Ld fasting glucose (mmol/L) | 6.83 ± 1.67 | 7.38 ± 1.61 | ns |
| Mean pre-Ld fasting glucose (mmol/L) | 7.16 ± 1.50 | 7.44 ± 1.67 | ns |
| Last pre-Ld total cholesterol (mmol/L) | 4.32 ± 0.93 | 4.06 ± 0.98 | ns |
| Mean pre-Ld total cholesterol (mmol/L) | 4.37 ± 0.90 | 4.24 ± 0.83 | ns |
| Last pre-Ld LDL cholesterol (mmol/L) | 2.40 ± 0.80 | 2.04 ± 0.80 | ns |
| Mean pre-Ld LDL cholesterol (mmol/L) | 2.40 ± 0.52 | 2.20 ± 0.70 | ns |
| Last pre-Ld triglycerides (mmol/L) | 1.43 ± 0.68 | 1.73 ± 0.62 | 0.0458 |
| Mean pre-Ld triglycerides (mmol/L) | 1.51 ± 0.61 | 1.86 ± 0.77 | 0.0138 |
Ld lockdown; Mean pre-Ld mean of the last three values before the lockdown